iRadimed (NASDAQ:IRMD) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut shares of iRadimed (NASDAQ:IRMD) from a buy rating to a hold rating in a research note published on Saturday.

Separately, Weiss Ratings lowered iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, iRadimed presently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Stock Performance

iRadimed stock opened at $92.50 on Friday. iRadimed has a fifty-two week low of $67.84 and a fifty-two week high of $107.90. The stock’s 50 day simple moving average is $94.55 and its two-hundred day simple moving average is $95.40. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of 51.68 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. The firm had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts predict that iRadimed will post 1.52 earnings per share for the current year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Shareholders of record on Friday, August 14th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th. iRadimed’s payout ratio is 44.69%.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 17,500 shares of company stock valued at $1,515,065 over the last 90 days. Corporate insiders own 34.60% of the company’s stock.

Hedge Funds Weigh In On iRadimed

A number of hedge funds have recently bought and sold shares of IRMD. BlackRock Inc. purchased a new position in iRadimed in the second quarter worth about $92,485,000. Vanguard Group Inc. increased its position in shares of iRadimed by 1.0% during the third quarter. Vanguard Group Inc. now owns 566,507 shares of the medical equipment provider’s stock valued at $40,313,000 after acquiring an additional 5,475 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in iRadimed by 410.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after acquiring an additional 205,783 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after acquiring an additional 9,017 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after acquiring an additional 55,426 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.